David S. Alberts mainly investigates Internal medicine, Pharmacology, Oncology, Chemotherapy and Surgery. His studies deal with areas such as Gastroenterology and Endocrinology as well as Internal medicine. His Pharmacology research incorporates elements of Catechin, Epigallocatechin gallate, In vivo and Doxorubicin.
The study incorporates disciplines such as Peripheral neuropathy, Cancer and Interim analysis in addition to Oncology. His Chemotherapy study incorporates themes from Regimen, Anesthesia and Metastatic breast cancer. His Surgery study combines topics from a wide range of disciplines, such as Toxicity and Urology.
The scientist’s investigation covers issues in Internal medicine, Oncology, Pharmacology, Chemotherapy and Cancer. His Internal medicine study combines topics in areas such as Gastroenterology, Endocrinology and Surgery. His study in Oncology is interdisciplinary in nature, drawing from both Regimen, Disease, Cisplatin and Group study.
His research investigates the connection between Pharmacology and topics such as In vivo that intersect with problems in In vitro. His Chemotherapy research includes elements of Nausea and Vomiting. His work focuses on many connections between Cancer and other disciplines, such as Pathology, that overlap with his field of interest in Karyometry and Skin cancer.
His primary areas of investigation include Internal medicine, Oncology, Cancer, Ovarian cancer and Pathology. Clinical trial, Randomized controlled trial, Colorectal adenoma, Colorectal cancer and Gynecologic oncology are the core of his Internal medicine study. Randomized controlled trial is a subfield of Surgery that David S. Alberts studies.
His work deals with themes such as Bevacizumab, Chemotherapy, Cisplatin, Regimen and Disease, which intersect with Oncology. His Cancer research is multidisciplinary, incorporating elements of Melanoma, Pharmacology and Family medicine. Alternative medicine is closely connected to Gynecology in his research, which is encompassed under the umbrella topic of Ovarian cancer.
David S. Alberts mostly deals with Internal medicine, Oncology, Randomized controlled trial, Ovarian cancer and Clinical trial. His work on Placebo expands to the thematically related Internal medicine. His biological study spans a wide range of topics, including Bevacizumab, Chemotherapy regimen, Chemotherapy and Regimen.
While the research belongs to areas of Regimen, David S. Alberts spends his time largely on the problem of Taxane, intersecting his research to questions surrounding Pharmacology. His Randomized controlled trial study deals with the bigger picture of Surgery. The concepts of his Ovarian cancer study are interwoven with issues in Carboplatin, Quality of life, Isoflavones and Gynecology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
William A. Peters;P.Y. Liu;Rolland J. Barrett;Richard J. Stock.
Journal of Clinical Oncology (2000)
Molecular classification of cutaneous malignant melanoma by gene expression profiling
M. Bittner;P.S.J. Meltzer;Y.D. Chen;Y. Jiang.
Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials.
Janine G. Einspahr;David S. Alberts;Susan M. Gapstur;Roberd M. Bostick.
Cancer Epidemiology, Biomarkers & Prevention (1997)
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
David S. Alberts;P. Y. Liu;Edward V. Hannigan;Robert O'Toole.
The New England Journal of Medicine (1996)
Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group
Maurie Markman;Brian N. Bundy;David S. Alberts;Jeffrey M. Fowler.
Journal of Clinical Oncology (2001)
Quantitation of Differential Sensitivity of Human-Tumor Stem Cells to Anticancer Drugs
Sydney E. Salmon;Anne W. Hamburger;Barbara Soehnlen;Brian G. M. Durie.
The New England Journal of Medicine (1978)
The national lung screening trial: Overview and study design
Constantine A. Gatsonis;Denise R. Aberle;Christine D. Berg;William C. Black.
Reducing Uncertainties About the Effects of Chemoradiotherapy for Cervical Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 18 Randomized Trials
Claire Vale;Jayne F. Tierney;Lesley A. Stewart;Mark Brady.
Journal of Clinical Oncology (2008)
Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4
George Pettit;S. B. Singh;E. Hamel;C. M. Lin.
Cellular and Molecular Life Sciences (1989)
Ovarian Cancer: Screening, Treatment, and Follow-up
Vicki Seltzer;Bruce H. Drukker;Brenda W. Gillespie;Lynn M. Gossfeld.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: